VIA
PTGX icon

Virtus Investment Advisers’s Protagonist Therapeutics PTGX Stock Holding History

Virtus Investment Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$301K Buy
2,860
+70
+3% +$6.2K 0.08% 277
2025
Q4 		$244K Buy
2,790
+770
+38% +$63K 0.07% 341
2025
Q3 		$134K Buy
2,020
+350
+21% +$19.9K 0.04% 394
2025
Q2 		$92.3K Sell
1,670
-2,395
-59% -$115K 0.03% 364
2025
Q1 		$197K Buy
+4,065
New +$170K 0.05% 265

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Virtus Investment Advisers's PTGX Position: Q1 2026 in Review

Virtus Investment Advisers increased its Protagonist Therapeutics (PTGX) stake by 2.5% in Q1 2026, buying an estimated $6.2K and bringing the position to 2,860 shares worth $301K. The position accounts for 0.08% of the portfolio, ranked #277.

Virtus Investment Advisers first reported a position in PTGX in Q1 2025 and has held it in 5 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Virtus Investment Advisers held 2,860 shares of Protagonist Therapeutics worth $301K as of Q1 2026.
  • Virtus Investment Advisers bought 70 Protagonist Therapeutics shares in Q1 2026, an estimated $6.2K.
  • Protagonist Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #277 holding.
  • Virtus Investment Advisers first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.